Table 1. Study characteristics with matuzumab given as multiple 1 h i.v. infusions ranging from 400 to 2000 mg, q1w–q3w.

Study	Tumour entity	Dose regimen	Planned sampling timesa	No. of subjects
1	Advanced pancreatic cancer	400 mg q1w; 800 mg q2w; 800 mg q1w	Baseline, 1, 2, 5, 48, 96, 168, 672, 673, 674, 677, 720, 840b	17
2	Various advanced cancer (mainly colon/rectum cancer)	1200 mg q1w, q2w, q3w; 400 mg q3w; 800 mg q3w; 1600 mg q3w	For q1w: baseline, 1, 2, 5, 48, 96, 168b; for q2w: baseline, 1, 2, 5, 48, 96, 168, 336b; for q3w: baseline, 1, 2, 5, 48, 168, 336, 504, 505, 506, 509, 552, 672, 840, 1008b	51
3	Various advanced cancer (mainly colon/rectum cancer)	400 mg q1w; 800 mg q1w; 1200 mg q1w; 1600 mg q1w; 2000 mg q1w (from week2: 1600 mg)	Baseline, 1, 2, 5, 24, 72, 96, 168, 504, 505, 506, 509, 528, 576, 600, 672b	22

^aRelative time elapsed after start of first infusion, in hours.

^bBefore and after several other infusions peak and trough concentrations were analysed.